ProMIS Neurosciences, Inc.
PMNHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ProMIS Neurosciences, Inc. focuses on Biotechnology services and products. ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. With a market capitalization of $74.8M, it sits in micro-cap territory. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing.
Market Cap
$74.8M
Beta
-0.25
P/E (TTM)
—
P/E (Fwd)
-1.83
EPS (TTM)
$-11.65
EPS (Fwd)
$-4.55
ROE
-172.3%
ROA
-81.1%
Cash
$53.5M
Total Debt
$0
Free CF
-$26.8M
52W Change
-22.4%
Annual Financials
Cash vs Debt
Where PMN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PMN finished 32.98% below its 150-day moving average ($12.28) and 36.00% below its 200-day moving average ($12.86). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PMN overbought or oversold?
At the October 20, 2026 close, PMN's RSI(14) was 25.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
ProMIS Neurosciences, Inc. reports $53.5M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$26.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -172.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of -0.25 suggests PMN is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ProMIS Neurosciences, Inc. and its sector.